[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100398490":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":11,"locations":42,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A: BMS-986278 suspension, fasted","EXPERIMENTAL",null,[13],"Drug: BMS-986278 suspension",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment B: BMS-986278 tablet, fasted",[17],"Drug: BMS-986278 Tablet",{"label":19,"type":10,"description":11,"interventionNames":20},"Treatment C: BMS-986278 tablet, fed",[17],{"label":22,"type":10,"description":11,"interventionNames":23},"Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted",[17,24],"Drug: Esomeprazole",[26,31,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","BMS-986278 Tablet","Specified dose on specified days",[15,19,22],{"type":27,"name":32,"description":29,"armGroupLabels":33,"otherNames":34},"Esomeprazole",[22],[35],"NEXIUM",{"type":27,"name":37,"description":29,"armGroupLabels":38,"otherNames":11},"BMS-986278 suspension",[9],[40],{"name":5,"affiliation":5,"role":41},"STUDY_DIRECTOR",[43],{"facility":44,"status":11,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":11},"ICON (LPRA) - Salt Lake","Salt Lake City","Utah","84124","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-111.89105,40.76078,{"lat":54,"lon":53},{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100398490","phase-1-a-study-to-assess-the-levels-in-blood-plasma-of-bms-986278-in-healthy-participants-following-administration-of-tablets-with-or-without-food-and-in-the-presence-of-an-antacid-esomeprazole-100398490",false,"NCT04468815","A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)","An Open-Label Study to Assess Relative Bioavailability, Food Effect, and Esomeprazole Drug-Drug Interaction of BMS-986278 Tablets Following a Single Dose Administration in Healthy Participants","Inclusion Criteria:\n\n* Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator\n* Women and men must agree to follow specific methods of contraception\n\nExclusion Criteria:\n\n* Women of childbearing potential (WOCBP) and Women who are pregnant or breastfeeding\n* Any significant acute or chronic medical condition that presents a potential risk to the participant and\u002For that may compromise the objectives of the study\n* Exposure to any investigational drug or placebo within 4 weeks of first study treatment administration.\n* History of any significant drug and\u002For food allergies (such as anaphylaxis or hepatotoxicity)\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply",true,"ALL","21 Years","65 Years",{"count":70,"type":71},24,"ACTUAL","INTERVENTIONAL",[74],"PHASE1","The purpose of this study is to assess levels in blood plasma of BMS-986278 and the food effect in healthy participants.",[77],"Healthy Participants","COMPLETED","2022-05-05",{"date":81,"type":71},"2022-05-10",{"date":83,"type":71},"2020-07-10",{"date":85,"type":71},"2020-10-07",{"name":5,"class":6},1]